John Leonard, Intellia CEO
September 16, 2022 11:35 AM EDT
R&D

Along­side promis­ing first HAE da­ta, In­tel­lia posts read­out in Re­gen­eron-part­nered AT­TR pro­gram

Lei Lei Wu

News Reporter

In Au­gust, Al­ny­lam tout­ed a Phase III suc­cess for transthyretin amy­loi­do­sis, or AT­TR for short, with car­diomy­opa­thy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times